Personalized treatment approaches for a rare type of Hodgkin lymphoma
Official title: Investigating personalized approaches to de-intensify therapy for nodular lymphocyte-predominant Hodgkin lymphoma
Funded at Stanford University · NIH-10948864 · Data updated 2026-11-12
This study is looking to create personalized treatment plans for people with nodular lymphocyte-predominant Hodgkin lymphoma by examining their tumor and blood samples to find out which therapies might work best for them, helping to reduce side effects while still being effective.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $284,784 |
| NIH project number | 1K08CA266824-01A1 |
| Project ID | NIH-10948864 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma who are seeking personalized treatment options.
✕Less likely to help
Patients with other types of Hodgkin lymphoma or those who do not have a diagnosis of lymphoma may not benefit from this research.
What this research studies
This research focuses on developing personalized treatment strategies for patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). By analyzing tumor and blood samples, the study aims to identify specific genomic and microenvironmental factors that can predict how well patients will respond to different therapies. The approach combines expertise in cancer biology, biostatistics, and predictive modeling to optimize treatment plans, potentially reducing the intensity of therapy while maintaining effectiveness. Patients may benefit from a more tailored approach to their treatment, which could lead to fewer side effects and better outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less intensive treatment options for patients with nodular lymphocyte-predominant Hodgkin lymphoma.
How similar studies have gone: Previous research has shown promise in using genomic and microenvironmental factors to personalize cancer treatment, indicating that this approach could be beneficial.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Binkley, Michael S — Stanford University
- Study coordinator: Binkley, Michael S
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Personalized de‑intensification of therapy for NLP Hodgkin lymphoma
A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.